IHI Aerospace Stock Falls 8.8% on Weakness, June 03

IHI Corporation’s US-traded shares fell 8.8% to $15.35 USD on June 03, marking a sharp one-day decline for the Tokyo-based aerospace and industrial machinery company. The stock has lost 45.4% over the past three months as investors reassess valuations in the aerospace and defense sector. Despite the weakness, Meyka rates the stock B+ with a 12-month price target of $32.52 USD, suggesting significant upside from current levels.

Sharp Decline Signals Profit-Taking

IHICY fell 8.8% to $15.35 USD on June 03, with the stock down 45.4% over three months and 13.1% year-to-date. Volume surged to 183,686 shares, well above the 116,749 average. The decline came despite Meyka’s B+ rating and analyst consensus of Hold, indicating investors are taking profits after earlier gains.

Meyka Forecast Points to Recovery Potential

Meyka’s 12-month price target stands at $32.52 USD, implying 112% upside from current prices. The company’s B+ grade reflects strong return on equity at 29.1% and solid profitability metrics. Free cash flow grew 103% year-over-year, and earnings per share reached $0.95, supporting the constructive long-term view.

Valuation Metrics Show Oversold Conditions

IHICY trades at 15.7x trailing earnings and 1.55x sales, below historical averages for aerospace suppliers. The RSI at 32.15 signals oversold conditions, while the CCI at -208.49 indicates extreme weakness. Meyka’s technical indicators suggest the stock may be due for a bounce as sentiment extremes often precede reversals.

Sector Headwinds Weigh on Aerospace Stocks

Howmet Aerospace (48Z.DE) also faces pressure, trading at 59.9x earnings with a Meyka B+ rating. Both companies operate in the capital-intensive aerospace and defense sector, where supply chain constraints and rising input costs continue to pressure margins. However, long-term demand from commercial aviation and defense spending remains strong.

Final Thoughts

With Meyka rating IHICY B+ and targeting $32.52 USD, the 8.8% decline creates a buying opportunity for patient investors. Oversold technical signals and strong cash flow generation suggest the stock has limited downside from current levels.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.